Alaska Medicaid Pharmacy and Therapeutics Committee Meeting September 16, 2022

Please note, as a result of COVID-19 this meeting will be available via teleconference only.

Please register for the meeting by using the link below:

https://magellanhealth.zoom.us/webinar/register/WN_9u2rxHXaSrCgqhqldSCFgQ

If you are calling in only through the webinar:

*6 to Toggle mute/unmute and *9 to Raise Hand

After registering, you will receive a confirmation email containing information about joining the webinar.

Agenda

Public Call in toll free: 1-877-853-5247

Call to Order – Chair
Roll Call
8:00 am
8:05 am

3. Public Comment

The Department's methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where **new information exists and industry testimony will be taken. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

**New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.

4. Class review, discussion & vote.

AK Treatment Class	Drug Class	Status
Gastrointestinal	Antiemetic-Antivertigo Agents	GREEN
	GI Motility & Irritable Bowel Syndrome, Chronic	GREEN
	Ulcerative Colitis	GREEN
	Cytokine & Cell-Adhesion Molecules (CAM) Antagonist – GI indicated	BLUE
	Proton Pump Inhibitors	RED
Endocrine/ Metabolic	Antihyperuricemics	GREEN
	Progestins for Cachexia	GREEN
	Growth Hormone	RED
	Androgenic Agents, Topical	GREEN
	Bone Resorption Inhibitors	GREEN
	Glucagon Agents	RED
	Hypoglycemics, Metformin	GREEN
	Hypoglycemics, Alpha-Glucosidase Inhibitors	GREEN
	Hypoglycemics, SGLT2 Inhibitors	BLUE
	Hypoglycemics, Meglitinides	GREEN
	Hypoglycemics, Thiazolidinedione (TZD) and Combinations	GREEN
	Hypoglycemics, Dipeptidyl Peptidase-4 Inhib. (DPP-4) and Combinations	GREEN
	Hypoglycemics, Glucagon-like Peptide-1 (GLP-1) and Combinations	RED
	Rapid-Acting Insulins	GREEN
	Regular Insulins	GREEN
	Intermediate Insulins	GREEN

	Rapid/Intermediate-Acting Combination Insulins	GREEN
	Regular/Intermediate-Acting Combination Insulins	GREEN
	Long-Acting Insulins	BLUE
	Phosphate Binders	GREEN
Antiretrovirals	HIV/AIDs	RED
Single Class Review	Movement Disorders	GREEN
	Continuous Glucose Monitors	GREEN

Break as needed – 15 minutes

- 7. **Review minutes** from **April 2022** meeting
- **8.** Comments from Committee Members or Chair
- 9. Adjourn

Next Meeting Date: November 18, 2022